NLTX RSI Chart
Last 7 days
287.6%
Last 30 days
297.7%
Last 90 days
266.9%
Trailing 12 Months
555.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 05, 2023 | baker bros. advisors lp | acquired | - | - | 592,650 | - |
Aug 17, 2023 | baker bros. advisors lp | bought | 115,617 | 0.692559 | 166,942 | - |
Aug 16, 2023 | baker bros. advisors lp | bought | 156,254 | 0.680548 | 229,600 | - |
Aug 15, 2023 | baker bros. advisors lp | bought | 1,191,620 | 0.630885 | 1,888,800 | - |
Aug 11, 2023 | smith sean michael | sold | -818 | 0.6184 | -1,323 | interim cfo, prin acct off |
Aug 10, 2023 | smith sean michael | acquired | - | - | 5,000 | interim cfo, prin acct off |
Apr 03, 2023 | patel priti | sold | -2,607 | 0.6919 | -3,769 | - |
Mar 31, 2023 | patel priti | acquired | - | - | 10,000 | - |
Feb 02, 2023 | patel priti | sold | -8,587 | 0.5972 | -14,380 | chief medical officer |
Feb 02, 2023 | smith sean michael | sold | -1,980 | 0.5972 | -3,316 | principal accounting officer |
Which funds bought or sold NLTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Aug 09, 2023 | Endurance Wealth Management, Inc. | sold off | -100 | -14,000 | - | -% |
Nov 03, 2022 | ACT CAPITAL MANAGEMENT, LLC | unchanged | - | -78,000 | 127,000 | 0.17% |
Oct 17, 2022 | Highland Private Wealth Management | unchanged | - | -18,000 | 30,000 | -% |
May 16, 2022 | Amalgamated Financial Corp. | new | - | 9,000 | 9,000 | -% |
May 16, 2022 | Parametric Portfolio Associates LLC | added | 7.17 | -305,000 | 220,000 | -% |
Apr 04, 2022 | Dixon Hughes Goodman Wealth Advisors LLC | new | - | - | - | -% |
Aug 16, 2021 | PICTET ASSET MANAGEMENT LTD | added | 1.78 | -5,856,000 | 18,865,000 | 0.02% |
Unveiling Neoleukin Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Neoleukin Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Neoleukin Therapeutics Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -12.2% | 195 | 223 | 90.00 | 94.00 | 98.00 | 109 | 127 | 137 | 149 | 163 | 176 | 187 | 200 | 211 | 222 | 145 | 153 | 147 | 70.00 | 74.00 | 75.00 |
Current Assets | -13.1% | 174 | 200 | 80.00 | 84.00 | 86.00 | 85.00 | 109 | 118 | 130 | 144 | 156 | 167 | 181 | 195 | 207 | 131 | 140 | 144 | 68.00 | 73.00 | 75.00 |
Cash Equivalents | 1.5% | 150 | 148 | 25.00 | 31.00 | 35.00 | 82.00 | 41.00 | 78.00 | 129 | 71.00 | 156 | 165 | 179 | 193 | 202 | 130 | 140 | 143 | 66.00 | 73.00 | 74.00 |
Net PPE | -4.1% | 16.00 | 17.00 | 0.00 | 1.00 | 2.00 | 20.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 4.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 |
Liabilities | -32.8% | 25.00 | 37.00 | 14.00 | 14.00 | 17.00 | 11.00 | 21.00 | 20.00 | 19.00 | 20.00 | 21.00 | 20.00 | 21.00 | 19.00 | 21.00 | 17.00 | 16.00 | 5.00 | 3.00 | 1.00 | 4.00 |
Current Liabilities | -48.6% | 12.00 | 23.00 | 5.00 | 5.00 | 7.00 | 7.00 | 10.00 | 9.00 | 8.00 | 9.00 | 9.00 | 8.00 | 8.00 | 8.00 | 10.00 | 6.00 | 6.00 | 5.00 | 3.00 | 1.00 | 4.00 |
Shareholder's Equity | -8.2% | 171 | 186 | 75.00 | 80.00 | 81.00 | 94.00 | 106 | 117 | 130 | 143 | 155 | 167 | 179 | 191 | 200 | 129 | 137 | 142 | 67.00 | 72.00 | 72.00 |
Retained Earnings | -9.0% | -204 | -187 | -471 | -467 | -465 | -150 | -437 | -424 | -408 | -393 | -378 | -362 | -347 | -332 | -320 | -317 | -308 | -299 | -291 | -232 | -232 |
Additional Paid-In Capital | 0.4% | 375 | 373 | 547 | 547 | 547 | 5.00 | 543 | 541 | 539 | 536 | 533 | 530 | 527 | 524 | 521 | 447 | 445 | 441 | 358 | 305 | 304 |
Shares Outstanding | 0.3% | 13.00 | 13.00 | 9.00 | 9.00 | 9.00 | 9.00 | 11.00 | 11.00 | 11.00 | 8.00 | 11.00 | 11.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 33.00 | - | - | - | 36.00 | - | - | - | 323 | - | - | - | 546 | - | - | - | 24.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 28.0% | -21,650 | -30,071 | -4,269 | -4,049 | -13,033 | -18,150 | -9,289 | -11,294 | -14,091 | -12,168 | -8,756 | -13,276 | -13,358 | -9,229 | -112 | -8,794 | -6,440 | -4,636 | -6,532 | -1,470 | -2,756 |
Share Based Compensation | 478.6% | 1,045 | -276 | 172 | 331 | 1,191 | -5,537 | 2,031 | 2,312 | 2,446 | 3,009 | 3,210 | 2,918 | 2,420 | 2,229 | 1,688 | 1,022 | 683 | 666 | 5,151 | 788 | 1,078 |
Cashflow From Investing | 76.5% | 29,935 | 16,956 | -1,614 | -411 | 10,706 | 65,371 | -27,850 | -39,299 | -452 | -396 | -587 | -1,191 | -1,089 | -653 | -487 | -972 | -107 | -782 | - | - | - |
Cashflow From Financing | -107.0% | -6,524 | 92,843 | -1.00 | -294 | -66.00 | 66,388 | -52.00 | 62.00 | 133 | 107 | 32.00 | 311 | 282 | 1,288 | 72,156 | 301 | 3,390 | 82,204 | 37.00 | -2.00 | -2.00 |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Operating expenses: | ||||
Research and development expenses | $ 13,541 | $ 10,283 | ||
General and administrative expenses | 5,238 | 2,752 | ||
Total operating expenses | 18,779 | 13,035 | ||
Loss from operations | (18,779) | (13,035) | ||
Other income (expense): | ||||
Interest income | 2,320 | 777 | ||
Interest expense | (3) | (2) | ||
Other income | 143 | 0 | ||
Other expense | (602) | (3) | ||
Net loss | $ (16,921) | (12,263) | ||
Per share information | ||||
Net income (loss) per share, basic (in dollars per share) | [1] | $ (1.00) | ||
Net income (loss) per share, diluted (in dollars per share) | [1] | $ (1.00) | ||
Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares) | [1] | 16,903,735 | ||
Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares) | [1] | 16,903,735 | ||
Class A Common Stock | ||||
Other income (expense): | ||||
Net loss | $ (12,263) | |||
Per share information | ||||
Net income (loss) per share, basic (in dollars per share) | [1] | $ (28.28) | ||
Net income (loss) per share, diluted (in dollars per share) | [1] | $ (28.28) | ||
Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares) | [1] | 433,623 | ||
Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares) | [1] | 433,623 | ||
Class B Common Stock | ||||
Other income (expense): | ||||
Net loss | $ 0 | |||
Per share information | ||||
Net income (loss) per share, basic (in dollars per share) | $ 0 | |||
Net income (loss) per share, diluted (in dollars per share) | $ 0 | |||
Weighted-average shares outstanding used in computing net income (loss) per share, basic (in shares) | 0 | |||
Weighted-average shares outstanding used in computing net income (loss) per share, diluted (in shares) | 0 | |||
|
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 150,140 | $ 148,210 |
Short-term investments | 19,393 | 48,947 |
Prepaid expenses and other current assets | 4,608 | 3,191 |
Total current assets | 174,141 | 200,348 |
Property and equipment, net | 16,475 | 17,174 |
Operating lease right-of-use assets | 3,565 | 3,681 |
Finance lease right-of-use assets | 87 | 98 |
Restricted cash | 339 | 508 |
Other non-current assets | 743 | 764 |
Total assets | 195,350 | 222,573 |
Current liabilities: | ||
Accounts payable | 1,522 | 2,596 |
Accrued expenses and other current liabilities | 6,824 | 17,495 |
Operating lease liabilities, current | 2,670 | 2,559 |
Finance lease liabilities, current | 43 | 42 |
Lease contingent value rights liability, current | 430 | 281 |
Intellectual property contingent value rights liability | 329 | 0 |
Total current liabilities | 11,818 | 22,973 |
Operating lease liabilities, non-current | 11,642 | 12,302 |
Finance lease liabilities, non-current | 53 | 65 |
Lease contingent value rights liability, non-current | 857 | 1,006 |
Other liabilities | 203 | 203 |
Total liabilities | 24,573 | 36,549 |
Stockholders' equity: | ||
Preferred stock, $0.000001 par value; $50,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.000001 par value; $450,000,000 shares authorized as of March 31, 2024 and December 31, 2023; $12,860,995 and $12,823,665 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Additional paid-in capital | 374,852 | 373,178 |
Accumulated deficit | (204,075) | (187,154) |
Total stockholders' equity | 170,777 | 186,024 |
Total liabilities and stockholders' equity | $ 195,350 | $ 222,573 |